Drug intelligence / Profile preview

Invixia

Development stage: Preclinical
Lead developer: InVixa
Modality: Small Molecules
Administration: Inhalation

Overview

Invixia (also referred to as InVixa) is an inhaled statin therapy being developed for the treatment of COVID-19 pneumonia and Acute Respiratory Distress Syndrome (ARDS). Developed by InVixa with investment from Therma Bright, the therapy utilizes a proprietary statin formulation delivered via inhalation to achieve high local therapeutic concentrations in the lungs while minimizing systemic exposure. The mechanism of action involves inhibiting the mevalonate pathway to modulate the hyper-inflammatory immune response (cytokine storm) that causes severe respiratory failure in COVID-19 and ARDS patients. As of 2024, the development program is in the preclinical stage.

Other names: InStatin

Targets

HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)

Beyond the preview

Go deeper on Invixia.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Invixia.

Explore the full profile